Beijing Holley-Cotec

Beijing Holley-Cotec Pharmaceuticals is a leading Chinese pharmaceutical company dedicated to the research, production, and international marketing of artemisinin-based antimalarial drugs. As a core member of the Holley Group, the company was instrumental in the global commercialization of Dihydroartemisinin, marketed under the brand name Cotecxin. It operates extensive manufacturing facilities that comply with international GMP standards, supplying essential medicines to malaria-endemic regions, particularly in Africa and Southeast Asia. The company's legacy is defined by its collaboration with the Academy of Military Medical Sciences and its role in establishing artemisinin combination therapies (ACTs) as the primary treatment for malaria worldwide. Beyond its flagship antimalarials, the company continues to expand its portfolio in the infectious disease space while maintaining a robust supply chain for artemisinin derivatives.